Levetiracetam Tablet, Film Coated
Product Images NDC 50090-7804

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 50090-7804). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Figure1)

This bar chart compares the percentage of patients across three groups: Placebo (7.4%, N=95), Levetiracetam 1000 mg/day tablet (37.1%, N=97), and Levetiracetam 3000 mg/day tablet (39.6%, N=101). The y-axis represents the percentage of patients up to 45%, with bars indicating outcomes for each treatment group.*

FDA Label Image

Figure2 (Figure2)

A bar chart comparing the percentage of patients across three groups: Placebo (N=111) at 6.3%, Levetiracetam Tablet 1000 mg/day (N=106) at 20.8%, and Levetiracetam Tablet 3000 mg/day (N=105) at 35.2%. The vertical axis is labeled '% of Patients' with values from 0% to 45%.*

FDA Label Image

Figure3 (Figure3)

A bar chart comparing the percentage of patients between two groups: Placebo and Levetiracetam 3000 mg/day. The chart displays approximately 14.4% of patients for the Placebo group (N=104) and about 39.4% of patients for the Levetiracetam 3000 mg/day group (N=180), with the y-axis representing the percentage of patients from 0% to 45%.*

FDA Label Image

Figure4 (Figure4)

A bar chart comparing the percentage of patients between two groups: Placebo (N=97) with 19.6% and Levetiracetam Tablet (N=101) with 44.6%. The vertical axis represents the percentage of patients from 0% to 45%.*

FDA Label Image

Figure5 (Figure5)

A bar chart comparing the percentage of patients between a placebo group and a Levetiracetam group. The y-axis represents the percentage of patients from 0% to 45%. The placebo group (N=51) shows approximately 19.6%, while the Levetiracetam group (N=58) shows around 43.1%. The chart highlights a difference in patient outcomes between the two groups.*

FDA Label Image

Figure6 (Figure6)

Bar chart comparing the percentage of patients responding to Placebo (45.2%, N=84) versus Levetiracetam (72.2%, N=79). The vertical axis represents the percentage of patients from 0% to 100%. This chart illustrates patient response rates for Levetiracetam 1000 mg oral tablets.*

FDA Label Image

Label Image (Lbl500907804)

Label for Levetiracetam USP 1000 mg film-coated tablets by A-S Medication Solutions. The label shows product NDC 50090-7804-1, lot number G6722-1, storage instructions at 77 degrees Fahrenheit, and package quantity of 60 tablets. It includes a QR code and directions to see the package insert for dosage information.*

FDA Label Image

Structure (Structure)

Chemical structure of levetiracetam, showing its molecular formula with a pyrrolidone ring and the side chains including an ethyl group and an amide group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.